Inhibition of RXR and PPARgamma Ameliorates Diet-induced Obesity and Type 2 Diabetes

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2001 Oct 3

PMID 11581301

Citations 102

Authors

T Yamauchi

H Waki

J Kamon

K Murakami

K Motojima

K Komeda

H Miki

N Kubota

Y Terauchi

A Tsuchida

N Tsuboyama-Kasaoka

N Yamauchi

T Ide

W Hori

S Kato

M Fukayama

Y Akanuma

O Ezaki

A Itai

R Nagai

S Kimura

K Tobe

H Kagechika

K Shudo

T Kadowaki

Affiliations

Soon will be listed here.

Abstract

PPARgamma is a ligand-activated transcription factor and functions as a heterodimer with a retinoid X receptor (RXR). Supraphysiological activation of PPARgamma by thiazolidinediones can reduce insulin resistance and hyperglycemia in type 2 diabetes, but these drugs can also cause weight gain. Quite unexpectedly, a moderate reduction of PPARgamma activity observed in heterozygous PPARgamma-deficient mice or the Pro12Ala polymorphism in human PPARgamma, has been shown to prevent insulin resistance and obesity induced by a high-fat diet. In this study, we investigated whether functional antagonism toward PPARgamma/RXR could be used to treat obesity and type 2 diabetes. We show herein that an RXR antagonist and a PPARgamma antagonist decrease triglyceride (TG) content in white adipose tissue, skeletal muscle, and liver. These inhibitors potentiated leptin's effects and increased fatty acid combustion and energy dissipation, thereby ameliorating HF diet-induced obesity and insulin resistance. Paradoxically, treatment of heterozygous PPARgamma-deficient mice with an RXR antagonist or a PPARgamma antagonist depletes white adipose tissue and markedly decreases leptin levels and energy dissipation, which increases TG content in skeletal muscle and the liver, thereby leading to the re-emergence of insulin resistance. Our data suggested that appropriate functional antagonism of PPARgamma/RXR may be a logical approach to protection against obesity and related diseases such as type 2 diabetes.

Citing Articles

expression in skeletal muscle in relationship with insulin sensitivity in normal-weight and obese volunteers.

Aleksandrowicz R, Straczkowski M J Diabetes Metab Disord. 2025; 24(1):51.

PMID: 39845905 PMC: 11748634. DOI: 10.1007/s40200-024-01546-9.

NERINE reveals rare variant associations in gene networks across multiple phenotypes and implicates an subnetwork in Parkinson's disease.

Nazeen S, Wang X, Morrow A, Strom R, Ethier E, Ritter D bioRxiv. 2025; .

PMID: 39829934 PMC: 11741352. DOI: 10.1101/2025.01.07.631688.

The farnesoid X receptor activates transcription independently of RXR at non-canonical response elements.

van der Veen S, Dijkstra J, Willemsen E, Houtman R, Milona A, Marchet N Nucleic Acids Res. 2024; 53(4).

PMID: 39657775 PMC: 11879013. DOI: 10.1093/nar/gkae1214.

Plant miR6262 Modulates the Expression of Metabolic and Thermogenic Genes in Human Hepatocytes and Adipocytes.

Diez-Sainz E, Milagro F, Aranaz P, Riezu-Boj J, Lorente-Cebrian S Nutrients. 2024; 16(18).

PMID: 39339747 PMC: 11435339. DOI: 10.3390/nu16183146.

Diet-induced Obesity: Pathophysiology, Consequences and Target Specific Therapeutic Strategies.

Banerjee M, Pandey V Curr Protein Pept Sci. 2024; 26(2):113-124.

PMID: 39225225 DOI: 10.2174/0113892037329528240827180820.

References

HEYMAN R, Mangelsdorf D, Dyck J, Stein R, Eichele G, Evans R . 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992; 68(2):397-406. DOI: 10.1016/0092-8674(92)90479-v. View

Ebisawa M, Umemiya H, Ohta K, Fukasawa H, Kawachi E, Christoffel G . Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chem Pharm Bull (Tokyo). 2000; 47(12):1778-86. DOI: 10.1248/cpb.47.1778. View

Unger R, Zhou Y, Orci L . Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A. 1999; 96(5):2327-32. PMC: 26783. DOI: 10.1073/pnas.96.5.2327. View

Miles P, Barak Y, He W, Evans R, Olefsky J . Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest. 2000; 105(3):287-92. PMC: 377448. DOI: 10.1172/JCI8538. View

Kliewer S, Forman B, Blumberg B, Ong E, Borgmeyer U, Mangelsdorf D . Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994; 91(15):7355-9. PMC: 44398. DOI: 10.1073/pnas.91.15.7355. View

Wright H, Clish C, Mikami T, Hauser S, Yanagi K, Hiramatsu R . A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem. 2000; 275(3):1873-7. DOI: 10.1074/jbc.275.3.1873. View

Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Takahashi Y . Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol. 1996; 16(6):3074-84. PMC: 231302. DOI: 10.1128/MCB.16.6.3074. View

Vidal-Puig A, Jimenez-Linan M, Lowell B, Hamann A, Hu E, Spiegelman B . Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest. 1996; 97(11):2553-61. PMC: 507341. DOI: 10.1172/JCI118703. View

Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K . The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem. 2001; 276(44):41245-54. DOI: 10.1074/jbc.M103241200. View

10.

Mukherjee R, Davies P, Crombie D, Bischoff E, Cesario R, Jow L . Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997; 386(6623):407-10. DOI: 10.1038/386407a0. View

11.

Spiegelman B, Flier J . Adipogenesis and obesity: rounding out the big picture. Cell. 1996; 87(3):377-89. DOI: 10.1016/s0092-8674(00)81359-8. View

12.

Imai T, Jiang M, Chambon P, Metzger D . Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes. Proc Natl Acad Sci U S A. 2001; 98(1):224-8. PMC: 14572. DOI: 10.1073/pnas.98.1.224. View

13.

Soukas A, Cohen P, Socci N, Friedman J . Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 2000; 14(8):963-80. PMC: 316534. View

14.

Moore K, Rosen E, Fitzgerald M, RANDOW F, Andersson L, Altshuler D . The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med. 2001; 7(1):41-7. DOI: 10.1038/83328. View

15.

Kersten S, Desvergne B, Wahli W . Roles of PPARs in health and disease. Nature. 2000; 405(6785):421-4. DOI: 10.1038/35013000. View

16.

Masuzaki H, Ogawa Y, Aizawa-Abe M, Hosoda K, Suga J, Ebihara K . Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes. 1999; 48(8):1615-22. DOI: 10.2337/diabetes.48.8.1615. View

17.

Friedman J . Obesity in the new millennium. Nature. 2000; 404(6778):632-4. DOI: 10.1038/35007504. View

18.

Lehmann J, Moore L, Wilkison W, Willson T, Kliewer S . An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995; 270(22):12953-6. DOI: 10.1074/jbc.270.22.12953. View

19.

Mangino M, Zografakis J, Murphy M, Anderson C . Improved and simplified tissue extraction method for quantitating long-chain acyl-coenzyme A thioesters with picomolar detection using high-performance liquid chromatography. J Chromatogr. 1992; 577(1):157-62. DOI: 10.1016/0378-4347(92)80612-t. View

20.

Kliewer S, Lenhard J, Willson T, Patel I, Morris D, Lehmann J . A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995; 83(5):813-9. DOI: 10.1016/0092-8674(95)90194-9. View